An exploratory study of dermal replacement therapy in the treatment of stage III pressure ulcers

Journal of Applied Research

Volumn 4, Issue 1, 2004, Pages 12-23

  Payne, Wyatt G ^a,b   Wright, Terry E ^a,b   Ochs, Diane ^a,b   Mannari, Rudolph J ^a,b   Robson, Martin C ^a,b   Edington, H ^c   Marston, W ^d   Drake, D ^e   Remsburg, R ^f   Falanga, V ^g   Gao, M ^h   Embil, J ⁱ   Lynde, C ^j  

^a Bay Pines VA Medical Center   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNC Wound Management Clinic   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g ROGER WILLIAMS MEDICAL CENTER   (United States)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ Diabet Foot/Complicated Wound Clin   (Canada)

^j Lynde Centre for Dermatology Canada   (Canada)

more..

Author keywords

Chronic wound; Dermal replacement; Pressure ulcer

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECUBITUS; DERMAL REPLACEMENT THERAPY; DEVICE; DISEASE SEVERITY; FEMALE; FIBROBLAST; HUMAN; INTERMETHOD COMPARISON; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; WOUND CLOSURE; WOUND DRESSING; WOUND HEALING;

EID: 6444230477     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Beckrich K, Aronovitch SA. Hospital-acquired pressure ulcers: a comparison of costs in medical vs. surgical patients. Nurs Econ. 1999;17:263-271.
2. Mian E, Mian M, Beghe F. Lyophilized type-I collagen and chronic leg ulcers. Int J Tissue React. 1991;13:257-269.
3. Bick RL, Scott RG. Stasis ulcers refractory to therapy-accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report. Clin Appl Thromb Hemost. 2001;7:21-24.
4. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen. 2000;8:13-25.
5. Ashcroft GS, Mills SJ, Lei K, et al. Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor. J Clin Invest. 2003;111:1309-1318.
6. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-447.
7. Bennett NT, Schultz GS. Growth factors and wound healing: Part II. Role in normal and chronic wound healing. Am J Surg. 1993;166:74-81.
8. Wahl SM, Wong H, McCartney-Francis N. Role of growth factors in inflammation and repair. J Cell Biochem. 1989;40:193-199.
9. Robson MC. The role of growth factors in the healing of chronic wounds. Wound Rep Reg. 1997;5:12-17.
10. Robson MC. Cytokine manipulation of the wound. Clin Plast Surg. 2003;30:57-65.
11. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987;327:239-242.
12. Nakamura T. Structure and function of hepatocyte growth factor. Prog Growth Factor Res. 1991;3:67-85.
13. Jiang WG, Hiscox S. Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. Histol Histopathol. 1997;12:537-555.
14. Moore K. Compromised wound healing: a scientific approach to treatment. Br J Community Nurs. 2003;8:274-278.
15. Roberts C, Mansbridge J. The scientific basis and differentiating features of Dermagraft. Can J Plast Surg. 2002;10(suppl A):6A-13A.
16. Edmonds ME, Foster AV, McColgan M. 'Dermagraft': a new treatment for diabetic foot ulcers. Diabet Med. 1997;14:1010-1011.
17. Purdue GF. Dermagraft-TC pivotal efficacy and safety study. J Burn Care Rehabil. 1997;18(1 Pt 2):S13-14.
18. Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care. 1996;19:350-354.
19. Payne WG, Ochs DE, Meltzer DD, et al. Long-term outcome study of growth factor-treated pressure ulcers. Am J Surg. 2001;181:81-86.
20. Brandeis GH, Morris JN, Nash DJ, Lipsitz LA. The epidemiology and natural history of pressure ulcers in elderly nursing home residents. JAMA. 1990;264:2905-2909.
21. Berlowitz DR, Brandeis GH, Anderson J, Brand HK. Predictors of pressure ulcer healing among long-term care residents. J Am Geriatr Soc. 1997;45:30-34.
22. Disa JJ, Carlton JM, Goldberg NH. Efficacy of operative cure in pressure sore patients. Plast Reconstr Surg. 1992;89:272-278.
23. Tanaka M, Nakakita N, Kuroyanagi Y. Allogeneic cultured dermal substitute composed of spongy collagen containing fibroblasts: evaluation in animal test. J Biomater Sci Polym Ed. 1999;10:433-453.
24. Mansbridge J, Liu K, Patch R, Symons K, Pinney E. Three-dimensional fibroblast culture implant for the treatment of diabetic foot ulcers: metabolic activity and therapeutic range. Tissue Eng. 1998;4:403-414.
25. Rennekampff HO, Hansbrough JF, Woods V, Jr., Kiessig V. Integrin and matrix molecule expression in cultured skin replacements. J Burn Care Rehabil. 1996;17:213-221.
26. Orsted H, Attrell E. The role of a biological device in Calgary Home Care: An exploration into efficacy and effectiveness. Can J Plast Surg. 2002;10(suppl A):54A-57A.
27. Robson MC, Hill DP, Smith PD, et al. Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response. Ann Surg. 2000;231:600-611.
28. Gilman TH. Parameter for measurement of wound closure. Wound 1990;2:95-101.
29. O'Meara S, Cullum N, Majid M, Sheldon T. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technol Assess. 2000;4:1-237.
30. Zimny S, Schatz H, Pfohl U. The effects of applied felted foam on wound healing and healing times in the therapy of neuropathic diabetic foot ulcers. Diabet Med. 2003;20:622-625.
31. Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003;26:1879-1882.
32. De Sanctis MT, Belcaro G, Cesarone MR, et al. Treatment of venous ulcers with pentoxifylline: a 12-month, double-blind, placebo controlled trial. Microcirculation and healing. Angiology. 2002;53(suppl 1):S49-S51.
33. Torra i Bou JE. Clinical evaluation of a hydro-cellular dressing for the treatment of venous leg ulcers. Rev Enferm. 1999;22:531-536.
34. Moody M. Comparison of Rosidal K and SurePress in the treatment of venous leg ulcers. Br J Nurs. 1999;8:345-355.
35. Resch CS, Kerner E, Robson MC, et al. Pressure sore volume measurement. A technique to document and record wound healing. J Am Geriatr Soc. 1988;36:444-446.
36. Hirschberg J, Coleman J, Marchant B, Rees RS. TGF-b3 in the treatment of pressure ulcers: A preliminary report. Adv Skin Wound Care. March/April 2001:91-95.
37. Margolis DJ, Gross EA, Wood CR, Lazarus GS. Planimetric rate of healing in venous ulcers of the leg treated with pressure bandage and hydrocolloid dressing. J Am Acad Dermatol. 1993;28:418-421.
38. Gorin DR, Cordts PR, LaMorte WW, Manzoian JO. The influence of wound geometry on the measurement of wound healing rates in clinical trials. J Vasc Surg. 1996;23:524-528.
39. Margolis DJ. Wound healing assessment: the clinical utility of wound healing rates. Ostomy Wound Manage. 1994;40:20-2, 24, 26-27.
40. Phillips TJ, Machado F, Trout R, Porter J, Olin J, Falanga V. Prognostic indicators in venous ulcers. J Am Acad Dermatol. 2000;43:627-630.
41. Bulstrode CJ, Goode AW, Scott PJ. Measurement and prediction of progress in delayed wound healing. J R Soc Med. 1987;80:210-212.
42. Kantor J, Margolis DJ. A multi-center study of percentage change in venous leg ulcer area as a prognostic index of healing at 24 weeks. Br J Dermatol. 2000;142:960-964.
43. Robson MC, Maggi SP, Smith PD, Wasserman RJ, Mosiello GC, et al. Ease of wound closure as an endpoint of treatment efficacy. Wound Rep Reg. 1999;7:90-96.
44. Banda MJ, Dwyer KS, Beckmann A. Wound fluid angiogenesis factor stimulates the directed migration of capillary endothelial cells. J Cell Biochem. 1985;29:183-193.